Innotive Diagnostics

Innotive Diagnostics (trading as InnotiveDx) is a Bath-based medical device company developing a rapid point-of-care diagnostic system for urinary tract infections (UTIs). Incorporated in 2019 under the name PhenUtest Diagnostics before rebranding in 2024, the company was founded to address a significant clinical and public health problem: the absence of fast, accurate antimicrobial susceptibility testing at the point of care.

Currently, patients with suspected UTIs must wait days for laboratory results before receiving targeted antibiotic treatment. In the interim, clinicians often prescribe broad-spectrum antibiotics empirically — a practice that contributes significantly to the growing global crisis of antimicrobial resistance (AMR). InnotiveDx's system aims to deliver a complete UTI diagnosis including full antimicrobial susceptibility test (AST) results within 60 minutes at the point of care, enabling clinicians to prescribe the right antibiotic immediately and eliminate unnecessary treatment delay and drug misuse.

The company has secured a £1 million grant from PACE (Pathogen Access to Critical Technologies), seed funding, and support from Innovate UK. It participated in the Innovate UK Global Incubator Program in partnership with Texas Medical Center Innovation, was longlisted for the Nature Spinoff Prize and was shortlisted for the BioNow Start-Up Award. InnotiveDx appointed a Director of Research and Development in 2025 as it advances towards clinical studies and regulatory clearance.